MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 16636248.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Patients with recurrent gliomas (n = 14) were treated with bevacizumab and carboplatin, cpt-11, or etoposide. Follow-up MRI scans were obtained 2 to 6 weeks after initiation of treatment. Contrast-enhancing tumor shrank in 7 patients, with reductions evident in as little as 2 weeks after initiation of therapy. Treatment seemed more effective for heterogeneously enhancing tumor compared with solidly enhancing tumor.
Medical subject headings
- Antibodies, Monoclonal
- Glioma